Co-Authors
This is a "connection" page, showing publications co-authored by Daniele Focosi and Marco Tuccori.
Connection Strength
3.920
-
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future. Expert Opin Drug Discov. 2021 12; 16(12):1403-1414.
Score: 0.959
-
Convalescent Plasma Therapy for COVID-19: State of the Art. Clin Microbiol Rev. 2020 09 16; 33(4).
Score: 0.897
-
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs. 2020 Jan-Dec; 12(1):1854149.
Score: 0.860
-
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. Viruses. 2021 06 23; 13(7).
Score: 0.238
-
The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19. Life (Basel). 2021 Feb 15; 11(2).
Score: 0.232
-
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs. Br J Clin Pharmacol. 2021 05; 87(5):2186-2188.
Score: 0.228
-
What is the optimal usage of coronavirus disease 2019 convalescent plasma donations? Clin Microbiol Infect. 2021 Feb; 27(2):163-165.
Score: 0.226
-
The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance. Drug Saf. 2020 08; 43(8):699-709.
Score: 0.224
-
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Crit Care. 2020 06 11; 24(1):331.
Score: 0.055